The Liu Wei Di Huang Wan is a formula of a traditional Chinese medicine that is used to treat asthma patients and has been shown to have several important properties,such as antioxidant and free radical scavenging act...The Liu Wei Di Huang Wan is a formula of a traditional Chinese medicine that is used to treat asthma patients and has been shown to have several important properties,such as antioxidant and free radical scavenging activities.The influence of an extract of Liu Wei Di Huang Wan on the labeling of blood constituents with technetium-99m was investigated.Anticoagulated blood(Wistar rats) was incubated with the extract,stannous chloride and technetium-99m,as sodium pertechnetate.Samples were centrifuged and aliquots of plasma and blood cells were separated and precipitated with trichloroacetic acid,to obtain soluble and insoluble fractions of the blood constituents.The percentage of radioactivity(%ATI) in all the fractions was determined.The analysis of the results shows that the extract at the highest concentration used(70 mg/mL) decreased significantly(P<0.05) the %ATI(from 96.48 ± 1.19 to 54.46 ± 7.38) on blood cells compartment,(from 81.11 ± 4.15 to 61.33 ± 4.74) on insoluble fractions of blood cells and(from 65.91 ± 2.44 to 13.15 ± 3.62) on insoluble fractions of plasma.In conclusion,the results suggest that the substances present on this extract can alter this labeling process,probably due to(i) redox properties(antioxidant and chelator activities) and/or(ii) specific actions in the binding sites where the 99mTc would be bound on the blood constituents.As a consequence,precaution is suggested on the interpretation of the nuclear medicine results from performed with blood constituents labeled with 99m Tc in patients that have undertaken LWDHW,although the current findings were obtained in experimental animal models.展开更多
目的观察六味地黄丸对狼疮肾炎患者糖基化终末产物受体(receptor for advanced glycation end products,RAGE)、单核细胞趋化蛋白1及趋化因子Fractalkine水平的影响,探讨六味地黄丸用于狼疮肾炎的临床疗效,以期为临床上狼疮肾炎的治疗...目的观察六味地黄丸对狼疮肾炎患者糖基化终末产物受体(receptor for advanced glycation end products,RAGE)、单核细胞趋化蛋白1及趋化因子Fractalkine水平的影响,探讨六味地黄丸用于狼疮肾炎的临床疗效,以期为临床上狼疮肾炎的治疗提供参考。方法收集大连大学附属中山医院2014年9月至2016年9月肾内科门诊收治的狼疮肾炎患者46例,其中男性25例,女性21例,按照随机数字表法原则分为观察组和对照组,每组23例,其中对照组给予甲泼尼龙0.5 g/d静脉滴注3 d后口服泼尼松片(0.6 mg·kg^(-1)·d^(-1))治疗,8周后逐渐减量至10 mg/d维持治疗;观察组在常规西医治疗的基础上给予浓缩六味地黄丸辅助治疗,8丸/次,3次/日,均进行8个疗程(16 d为一个疗程)治疗。分别比较2组患者治疗前、后糖基化终末产物受体、单核细胞趋化蛋白1及趋化因子Fractalkine水平以及2组患者的临床疗效进行观察。结果与对照组临床疗效相比,六味地黄丸观察组总有效率为78.3%,高于对照组的70.0%(P<0.05);与对照组治疗后相比,观察组治疗后糖基化终末产物受体、单核细胞趋化蛋白1、趋化因子Fractalkine水平显著低于对照组(P<0.05)。结论六味地黄丸辅助常规西药治疗狼疮肾炎能够降低糖基化终末产物受体、单核细胞趋化蛋白1以及趋化因子Fractalkine的表达,提示六味地黄丸能够通过减轻狼疮肾炎的相关指标对狼疮肾炎具有治疗作用,值得临床进一步推广。展开更多
基金supported by Funda o de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)Universidade do Estado do Rio de Janeiro(UERJ)+1 种基金Conselho Nacional de Pesquisa e Desenvolvimento (CNPq)Instituto Nacional do Cancer (INCa)
文摘The Liu Wei Di Huang Wan is a formula of a traditional Chinese medicine that is used to treat asthma patients and has been shown to have several important properties,such as antioxidant and free radical scavenging activities.The influence of an extract of Liu Wei Di Huang Wan on the labeling of blood constituents with technetium-99m was investigated.Anticoagulated blood(Wistar rats) was incubated with the extract,stannous chloride and technetium-99m,as sodium pertechnetate.Samples were centrifuged and aliquots of plasma and blood cells were separated and precipitated with trichloroacetic acid,to obtain soluble and insoluble fractions of the blood constituents.The percentage of radioactivity(%ATI) in all the fractions was determined.The analysis of the results shows that the extract at the highest concentration used(70 mg/mL) decreased significantly(P<0.05) the %ATI(from 96.48 ± 1.19 to 54.46 ± 7.38) on blood cells compartment,(from 81.11 ± 4.15 to 61.33 ± 4.74) on insoluble fractions of blood cells and(from 65.91 ± 2.44 to 13.15 ± 3.62) on insoluble fractions of plasma.In conclusion,the results suggest that the substances present on this extract can alter this labeling process,probably due to(i) redox properties(antioxidant and chelator activities) and/or(ii) specific actions in the binding sites where the 99mTc would be bound on the blood constituents.As a consequence,precaution is suggested on the interpretation of the nuclear medicine results from performed with blood constituents labeled with 99m Tc in patients that have undertaken LWDHW,although the current findings were obtained in experimental animal models.
